Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 6

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 6
---
 infusion. The CORDStrom platform leverages,
among other things, proprietary screening, pooling and expansion techniques to create off-the-shelf, allogeneic, pooled hucMSCs as medicines
to treat complex inflammatory diseases. CORDStrom products are designed to provide high-quality, off-the-shelf, batch-to-batch consistent,
scalable, cGMP manufactured, potent cellular medicines that can be produced at low cost and with repeatable specification independent
of donor characteristics. Initially developed at the INKmune manufacturing facilities utilizing UK academic grant funding, CORDStrom is
a mesenchymal stromal cell (“MSC”) product platform that shows promise as a first systemic therapy for potentially treating
RDEB and many other debilitating conditions. While the first generation CORDStrom product is agnostic to disease indication, the platform
enables creation of indication-specific products, which can be tuned for optimization of anti-inflammatory, immunomodulatory, wound healing,
and other characteristics.

The CORDStrom product
platform shares many similarities, including reagents, equipment, and procedures, with the Company’s INKmune oncology product, enabling
the Company to leverage economies of scale, experienced staff, and other resources to strategically manufacture both products in a rotational
campaign with resource and environmental efficiencies.

Children with RDEB have
skin that is damaged by even the smallest amount of friction which causes severe blistering, deep wounds, and scars. It is caused by a
fault in a gene that makes collagen, a protein that holds the skin layers together. There are limited options available for treatment,
none that adequately meet the needs of patients, and the condition gets worse over time, with most children reliant on a wheelchair as
they move into their teenage years. Many of those with an RDEB diagnosis tend to develop aggressive life-threatening skin cancer in adulthood
caused by the accumulated damage to their skin. The Company estimates roughly 4,500 people suffer from RDEB in the US, UK and EU
representing a large unmet opportunity to potentially provide routine clinical care to these children.

<div align='center'>S-1</div>

Since 2020, the Company
has supplied CORDStrom hucMSCs as an investigational medical product to the Great Ormond Street Hospital (“GOSH”), London,
in connection with the Mission EB study, which was primarily funded by a grant from the National Institute for Health and Care Research
(“NIHR”)